In breast cancer patients, AMH levels dropped from 3.07 ng/ml at baseline to 0.30 ± 0.50 ng/ml during chemotherapy, highlighting the immediate gonadotoxic effects of cancer treatment (22). This evidence concerns the gene AMH and breast carcinoma.